Exclusive Interview With Fred Saad

MediaMedic shared on LinkedIn:

“Exclusive Insights on mHSPC Treatment: Interview with Fred Saad.

In a recent Media Medic interview, our colleague El Bachir Mourabit had the privilege to speak with Dr. Fred Saad about breakthrough advancements in metastatic hormone-sensitive prostate cancer (mHSPC) treatment.

Dr. Saad emphasized the importance of combining androgen deprivation therapy (ADT) with ARPIs like apalutamide, enzalutamide, or abiraterone for improved survival.

He also shared promising results from the Phase 3 ARINOTE study, showcasing darolutamide with ADT as a safe and effective option, especially for patients who may not tolerate chemotherapy.”

Source: MediaMedic/LinkedIn